Immunohistochemical study of bone GLA protein in primary bone tumors

✍ Scribed by Renpei Lwasaki; Takao Yamamuro; Yoshihiko Kotoura; Hideo Okumura; Ryuichi Kasai; Yasuaki Nakashima

• Publisher: John Wiley and Sons
• Year: 1992
• Tongue: English
• Weight: 758 KB
• Volume: 70
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(19920801)70:3<619::aid-cncr2820700313>3.0.co;2-5

✦ Synopsis

Methods. The immunoreactivity of bone GLA protein (BGP) in primary bone tumors, including osteosarcoma, chondrosarcoma, malignant fibrous histiocytoma of bone (MFH), and giant cell tumor of bone (GCT), was investigated with anti-BGP rabbit serum and peroxidase-antiperoxidase complex.

As to intracellular localization, BGP antigenicity was detected in 33 of 35 cases of osteosarcoma and 12 of 25 cases of chondrosarcoma. However, there were no positive findings in all 15 cases of MFH or 20 cases of GCT. In chondrosarcoma, the frequency of positively stained cases increased according to pathologic grading (i.e., 3 of 14 cases of Grade 1,7 of 9 cases of Grade 2, and 2 of 2 cases of Grade 3). Although the multinucleated cells in MFH or GCT were not immunostained, BGP antigenicity was observed in the multinucleated cells of osteosarcoma (12 of 15 cases). In the matrix of osteosarcoma, BGP immunoreactivity of the tumorous osteoid was observed in 28 of 32 cases. However, in the matrices of chondrosarcoma, MFH, and GCT, BGP immunoreactivity was not observed.

These results suggest that the immunohistochemical study of BGP is useful for the differential diagnosis of bone tumors. Cancer